Metastatic Prostate Cancer

Oncology·MeSH: Prostatic Neoplasms

Prevalence

256.0 / 100K

Incidence

111.0 / 100K/yr

58 drugs in development·19 companies·32 clinical trials

Drug Pipeline by Phase

Approved(3)

Drug	Company
BRACAnalysis CDx	MYRIAD GENETICS INC (MYGN)
nilutamide	ANI PHARMACEUTICALS INC (ANIP)
xgeva	AMGEN INC (AMGN)

Phase 3(10)

Drug	Company
aaa617	Novartis AG (NVS)
abiraterone	GH Research PLC (GHRS)
AZD0516	ASTRAZENECA PLC (AZN)
AZD0754	ASTRAZENECA PLC (AZN)
AZD2287	ASTRAZENECA PLC (AZN)
AZD5305	ASTRAZENECA PLC (AZN)
azd8359	ASTRAZENECA PLC (AZN)
Enzalutamide	ARS Pharmaceuticals, Inc. (SPRY)
Metronidazole	Myovant Sciences Ltd. (MYOV)
PARP Inhibitors and Other Systemic Agents	KYNTRA BIO INC. (KYNB)

Phase 2(17)

Drug	Company
AAA617	Novartis AG (NVS)
Abiraterone acetate	UNITED THERAPEUTICS Corp (UTHR)
AZD9574	ASTRAZENECA PLC (AZN)
etrumadenant	Arcus Biosciences, Inc. (RCUS)
etrumadenant	Arcus Biosciences, Inc. (RCUS)
Etrumadenant	Arcus Biosciences, Inc. (RCUS)
GnRH analog	KYNTRA BIO INC. (KYNB)
i-131-1095	PROGENICS PHARMACEUTICALS INC (PGNX)
i-131-1095	ARS Pharmaceuticals, Inc. (SPRY)
jsb462	Novartis AG (NVS)
JSB462	Novartis AG (NVS)
Metronidazole	Royalty Pharma plc (RPRX)
Metronidazole	Janux Therapeutics, Inc. (JANX)
Metronidazole	ARS Pharmaceuticals, Inc. (SPRY)
Talazoparib	KYNTRA BIO INC. (KYNB)
Testosterone cypionate	UNITED THERAPEUTICS Corp (UTHR)
Testosterone enanthate	UNITED THERAPEUTICS Corp (UTHR)

Phase 1(19)

Drug	Company
[225ac]ac-aky-2519	Aktis Oncology Inc. (AKTS)
[64cu]cu-aky-2519	Aktis Oncology Inc. (AKTS)
abiraterone acetate 250 mg or	Oric Pharmaceuticals, Inc. (ORIC)
Apalutamide	Merus N.V. (MRUS)
apalutamide 60 mg or	Oric Pharmaceuticals, Inc. (ORIC)
arx517	GH Research PLC (GHRS)
ARX517	Royalty Pharma plc (RPRX)
ARX517	Myovant Sciences Ltd. (MYOV)
ARX517	Merus N.V. (MRUS)
ARX517	ARS Pharmaceuticals, Inc. (SPRY)
ARX517	Janux Therapeutics, Inc. (JANX)
Degarelix	ELI LILLY & Co (LLY)
enzalutamide 40 mg capsules or 40 mg and	Oric Pharmaceuticals, Inc. (ORIC)
GNRH-A Leuprolide Acetate	ELI LILLY & Co (LLY)
oric-533	Oric Pharmaceuticals, Inc. (ORIC)
oric-944	Oric Pharmaceuticals, Inc. (ORIC)
ORIC-944	KYNTRA BIO INC. (KYNB)
Quemliclustat	Arcus Biosciences, Inc. (RCUS)
tazemetostat	Epizyme, Inc. (EPZM)

Unknown(2)

Drug	Company
archival tumor dna sequencing	GH Research PLC (GHRS)
liquid biopsy	GH Research PLC (GHRS)

Phase 1/Phase 2(3)

Drug	Company
oric-114 dose 1 + amivantamab	Oric Pharmaceuticals, Inc. (ORIC)
oric-114 dose 2 + amivantamab	Oric Pharmaceuticals, Inc. (ORIC)
oric-114 dose 3 + amivantamab	Oric Pharmaceuticals, Inc. (ORIC)

Phase 4(4)

BioSniper tracks 58 drugs in development for Metastatic Prostate Cancer across 19 companies.

There are 32 clinical trials targeting Metastatic Prostate Cancer tracked by BioSniper.

The estimated prevalence of Metastatic Prostate Cancer is approximately 256.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.